Companies dominating the Asthma and COPD Drugs Landscape
- GlaxoSmithKline plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- CHIESI Farmaceutici S.p.A.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Abbott
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Asthma and COPD Drugs Market in 2025 is estimated at USD 43.06 billion.
The global market size was more than USD 40.5 billion in 2024 and is anticipated to grow at a CAGR of over 7.9%, reaching USD 108.83 billion revenue by 2037.
North America is expected to attain largest share by 2037, driven by growing healthcare infrastructure and favorable reimbursement policies for asthma and COPD treatments.
The major players in the market include GlaxoSmithKline plc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, CHIESI Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott.
